Form 8-K - Current report:
SEC Accession No. 0001140361-22-014460
Filing Date
2022-04-14
Accepted
2022-04-14 07:50:16
Documents
13
Period of Report
2022-04-14
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc10036370_8k.htm   iXBRL 8-K 29397
2 EXHIBIT 99.1 brhc10036370_ex99-1.htm EX-99.1 16360
  Complete submission text file 0001140361-22-014460.txt   189593

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA galt-20220414.xsd EX-101.SCH 3959
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE galt-20220414_lab.xml EX-101.LAB 22544
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE galt-20220414_pre.xml EX-101.PRE 16066
7 EXTRACTED XBRL INSTANCE DOCUMENT brhc10036370_8k_htm.xml XML 4243
Mailing Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071
Business Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071 678-620-3186
GALECTIN THERAPEUTICS INC (Filer) CIK: 0001133416 (see all company filings)

EIN.: 043562325 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-31791 | Film No.: 22826017
SIC: 2834 Pharmaceutical Preparations